AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2258142
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with high titer neutralizing antibodies
Trial: 7269436
Drug: Health resort
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health resort and sanatorium treatment
Trial: 31243733
Drug: Vaccine (VAC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (VAC, fed with basal diet and injected with NDV vaccine)
Trial: 31243733
Drug: Vaccine +
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine + Probiotic Bacillus cereus PAS38 (PBVAC)
Trial: 16602471
Drug: Different antibiotics
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different antibiotics (specific types not mentioned)
Trial: 11846850
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg, 1x daily for 3 days at week 2)
Trial: 6831292
Drug: Midazolam (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.08 mg.kg‐1)
Trial: 6831292
Drug: Hydroxyzine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (1.5 mg.kg‐1)
Trial: 6831292
Drug: Hyoscine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine (0.4 mg)
Trial: 6831292
Drug: Atropine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.4 mg)
Trial: 31752978
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual treatment by GPs)
Trial: 30044486
Drug: Naloxegol 25
RxNorm normalized name: naloxegol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxegol 25 mg daily
Trial: 30044486
Drug: Naloxegol 12.5
RxNorm normalized name: naloxegol 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxegol 12.5 mg daily
Trial: 27007995
Drug: Single-dose zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-dose zonisamide at 200 mg
Trial: 27007995
Drug: Single-dose zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-dose zonisamide at 300 mg
Trial: 27007995
Drug: Single-dose zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-dose zonisamide at 400 mg
Trial: 27007995
Drug: Multiple-dose zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Multiple-dose zonisamide at 300 mg for 14 days
Trial: 21722193
Drug: Overdenture supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overdenture supported by two implants with ball attachments (2IBA)
Trial: 21722193
Drug: Overdenture supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overdenture supported by four implants with a triple bar (4ITB)
Trial: 21722193
Drug: Overdenture supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overdenture supported by two implants with a bar (2ISB)
Trial: 15786427
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation (3 litres of polyethylene glycol)
Trial: 15786427
Drug: Surgery without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery without mechanical bowel preparation
Trial: 11963202
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors administered periprocedurally
Trial: 8577008
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (24-hour combined infusion with fat, amino acids, and glucose)
Trial: 8577008
Drug: Sequential infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential infusion (combined fat and amino acids during daytime and glucose alone during nighttime)
Trial: 8577008
Drug: Bolus infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus infusion (nutrition provided by bolus infusions during 1 hour followed by 2 hours without any infusion)
Trial: 1961129
Drug: Combined estrogen-progestogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined estrogen-progestogen therapy
Trial: 6420178
Drug: Cyclosporine or
RxNorm normalized name: cyclosporine Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine or methotrexate therapy
Trial: 28528605
Drug: Calcipotriene/Betamethasone dipropionate
RxNorm normalized name: calcipotriene/betamethasone dipropionate 0.005 %-0.064 % TOPICAL FOAM (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene/Betamethasone dipropionate ointment
Trial: 22763150
Drug: Leflunomide 100
RxNorm normalized name: leflunomide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide 100 mg/week
Trial: 22763150
Drug: Methotrexate 10
RxNorm normalized name: methotrexate 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 10 mg/week
Trial: 11040240
Drug: High-dose adrenomedullin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adrenomedullin (5.8 pmol.kg(‐1).min(‐1))
Trial: 11040240
Drug: Low-dose adrenomedullin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adrenomedullin (2.9 pmol.kg(‐1).min(‐1))
Trial: 9569805
Drug: Local metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local metronidazole treatment
Trial: 9569805
Drug: Systemic metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic metronidazole treatment
Trial: 8409183
Drug: dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dobutamine infusion
Trial: 31097858
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (standard protocol for 12 weeks, 3 sessions weekly for 60 minutes each)
Trial: 19430625
Drug: Ice pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice pretreatment (cooling + topical anesthesia + counterstimulation + distraction)
Trial: 19430625
Drug: Without ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Without ice pretreatment (topical anesthesia + counterstimulation + distraction)
Trial: 15498088
Drug: Glargine (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glargine (once daily at dinner-time)
Trial: 22933433
Drug: Medium fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium fructose (MF) at 40 g/day
Trial: 22933433
Drug: High fructose
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fructose (HF) at 80 g/day
Trial: 22933433
Drug: High glucose
RxNorm normalized name: ONE TOUCH HIGH GLUCOSE CONTROL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High glucose (HG) at 80 g/day
Trial: 22933433
Drug: High sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High sucrose (HS) at 80 g/day
Trial: 21909500
Drug: Semiannual topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semiannual topical fluoride application (elmex fluid)
Trial: 16507801
Drug: G-CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (10 microg/kg subcutaneously daily for 5 days)
Trial: 14725512
Drug: IM midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IM midazolam 0.04 mg.kg(‐1) (Group M1)
Trial: 14725512
Drug: IM midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IM midazolam 0.08 mg.kg(‐1) (Group M2)
Trial: 9048536
Drug: Inhaled furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled furosemide (30 mg)
Trial: 9048536
Drug: Inhaled cromolyn
RxNorm normalized name: cromolyn Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled cromolyn (30 mg)
Trial: 7864916
Drug: Laser vaporization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser vaporization treatment
Trial: 29861245
Drug: Pilates-based mat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates-based mat exercises (twice per week, 60-min per session for 16 weeks)
Trial: 24050312
Drug: MEDI-528 (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-528 (30, 100, 300 mg) every 2 weeks for 24 weeks
Trial: 24050312
Drug: MEDI-528 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-528 (30 mg, 100 mg, 300 mg)
Trial: 16556138
Drug: Etidronate treatment
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate treatment (oral, prior to sleep on dialysis days for 23 months)
Trial: 9004050
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of 33-40% in daily dosage
Trial: 9004050
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of 60-66% in daily dosage
Trial: 28104903
Drug: Traction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traction therapy with the Saunders device
Trial: 26025383
Drug: TEAS treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEAS treatment (30 minutes each day for 4 consecutive days during HDBR)
Trial: 23925377
Drug: Umbilical cord
RxNorm normalized name: Sus Scrofa Umbilical Cord
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical cord mesenchymal stem cell (MSC) therapy, administered as three transfusions at 1-month intervals over 12 months.
Trial: 23925377
Drug: Saline (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (control group), administered in parallel to six patients.
Trial: 21936892
Drug: EGML (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGML (2 g/day)
Trial: 21936892
Drug: GCE (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCE (2 g/day)
Trial: 16608033
Drug: Lamivudine plus
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine plus thymosin alpha1 therapy postoperatively
Trial: 14552498
Drug: Customary Outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customary Outpatient Care (CC)
Trial: 10465485
Drug: Lateral closed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral closed wedge high tibial osteotomy using AO/ASIF L-plate (Group B)
Trial: 8609324
Drug: Intravenous amiodarone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone, 5 mg/kg body weight in 30 min followed by 1,200 mg over 24 h
Trial: 1921738
Drug: Org OD
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org OD 14 (2.5 mg daily for 24 months)
Trial: 6311914
Drug: Multiple-dose IFN-alpha
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose IFN-alpha 2 (11.4 X 10(6) IU four times per day for four days)
Trial: 6311914
Drug: One daily
RxNorm normalized name: One Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One daily treatment of IFN-alpha 2 (42.8 X 10(6) IU once per day for five days)
Trial: 6311914
Drug: Both dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosage regimens of IFN-alpha 2
Trial: 3885670
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg prostaglandin E2 (PGE2) vaginal suppositories
Trial: 3885670
Drug: Combined method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined method of 3 mg PGE2 vaginal suppositories alternating with intranasal oxytocin
Trial: 24139548
Drug: Telemedicine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine treatment at home using a video conference system with monitoring equipment (spirometer, thermometer, pulse oximeter) and 24/7 online access to the hospital.
Trial: 24139548
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment at the hospital.
Trial: 20722752
Drug: Protease inhibitor-sparing
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-sparing arm (lopinavir/ritonavir+efavirenz)
Trial: 19050084
Drug: 150 microg
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microg x kg(‐1) morphine
Trial: 16550736
Drug: Content of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Content of capsule sprinkled on applesauce (Medikinet retard 20 mg)
Trial: 16550736
Drug: Intact capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact capsule (Medikinet retard 20 mg)
Trial: 10843243
Drug: Peritubular capillary
RxNorm normalized name: Artemisia capillaris leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritubular capillary flow in steroid resistant, MesP nephrosis
Trial: 8383518
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg rac-atenolol
Trial: 2876770
Drug: BCG treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG treatment.
Trial: 2876770
Drug: BCG treatment
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG treatment in pneumonectomized patients.
Trial: 2876770
Drug: BCG treatment
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG treatment vs placebo in lobectomies.
Trial: 29880427
Drug: Dobutamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (5 to 20 µg/kg/min) and Nitroglycerin (0.5 to 3 µg/kg/min)
Trial: 29880427
Drug: Milrinone (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (loading dose of 50 µg/kg over 10 minutes, followed by maintenance dose of 0.25 to 0.75 µg/kg/min)
Trial: 22622705
Drug: Auditory training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory training for 4 weeks, 1 hour a day, 5 days a week using both cochlear implant and hearing aid devices.
Trial: 20820984
Drug: Docetaxel 45
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 45 mg/m² with bolus/44-h infusion of 5-Fluorouracil/leucovorin (5-Fu/Lv)
Trial: 20820984
Drug: Irinotecan 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg/m² with bolus/44-h infusion of 5-Fluorouracil/leucovorin (5-Fu/Lv)
Trial: 9110111
Drug: Propantheline bromide,
RxNorm normalized name: Propantheline Bromide, 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propantheline bromide, 64.3 (+/‐ 21.8) mg/day for 7 days, followed by 30 mg orally before repeat tilt-table testing.
Trial: 9110111
Drug: Propantheline bromide
RxNorm normalized name: Propantheline Bromide
DrugBank: Propantheline (DB00782)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propantheline bromide treatment
Trial: 1514336
Drug: Single-dose spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose spinal anaesthesia with 3 ml of plain 0.5% bupivacaine (SDSA group)
Trial: 1514336
Drug: Continuous spinal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous spinal anaesthesia using a 32- or 22-gauge catheter with a bolus of 1.0 ml or 0.5 ml of plain 0.5% bupivacaine followed by an infusion at a rate of 2 ml/h (CSA group)
Trial: 1514336
Drug: Single-dose spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose spinal anaesthesia (SDSA group)
Trial: 3906163
Drug: Soybean phospholipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean phospholipid (18 g daily for 6 weeks)
Trial: 31230119
Drug: Intra-articular hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronic acid injection (3 injections weekly starting immediately after ORIF)
Trial: 31230119
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no injection after ORIF)
Trial: 22067476
Drug: Exenatide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (5 μg bolus in 30 minutes followed by continuous infusion of 20 μg/24 h for 72 h)
Trial: 17614243
Drug: Mandatory treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandatory treatment for repeat DUI offenders
Trial: 16925757
Drug: Docetaxel (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (70 mg/m² intravenously on day 2 every 21 days) and estramustine (3 x 280 mg/day oral for 5 consecutive days) with dexamethasone (16 mg total daily dose for 5 days)
Trial: 16925757
Drug: Estramustine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estramustine (3 x 140 mg/day oral for 3 consecutive days) with dexamethasone (16 mg total daily dose for 3 days)
Trial: 12924097
Drug: Inactivated split
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated split trivalent influenza vaccine (IIV), administered parenterally
Trial: 12924097
Drug: Live cold‐adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live cold‐adapted reassortant trivalent influenza vaccine (LIV), administered intranasally
Trial: 12924097
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both vaccines
Trial: 8777253
Drug: Chemotherapy before
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy before surgery
Trial: 30440099
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received no PRP injection)
Trial: 30360965
Drug: Erenumab 140
RxNorm normalized name: Erenumab 140 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 140 mg (via two 70 mg injections) every 4 weeks for 12 weeks
Trial: 27449267
Drug: Modified Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Sequential Oral Sensory Approach (M-SOS)
Trial: 24586031
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy - 20 mg omeprazole and 1 g amoxicillin for 5 days, followed by 20 mg omeprazole, 500 mg clarithromycin and 500 mg tinidazole for the successive 5 days
Trial: 24586031
Drug: 5 day
RxNorm normalized name: Fresh 5 Day Deodorant Pads
DrugBank: Aluminum chlorohydrate (DB11573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 day concomitant therapy - 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for 5 days
Trial: 24586031
Drug: 14 day
RxNorm normalized name: Ponvory 14 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day concomitant therapy - 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for 14 days
Trial: 24586031
Drug: Hybrid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid therapy - 20 mg omeprazole and 1 g amoxicillin for 7 days, followed by 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for the successive 7 days
Trial: 17942471
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (5 or 10 g/day) and rhGH (0, 3, or 5 microg/kg/day) for 16 weeks
Trial: 15020610
Drug: Three to
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three to four courses of high-dose cytarabine (HDAC)
Trial: 15020610
Drug: One course
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One course of high-dose cytarabine (HDAC) followed by alternative intensive consolidation therapy
Trial: 11937116
Drug: Dienogest, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest, 1 mg tablet daily for 16 weeks
Trial: 11937116
Drug: Decapeptyl, 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decapeptyl, 3.75 mg IM injection every 4 weeks for 16 weeks
Trial: 7038842
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with 5-FU and BCNU
Trial: 23716985
Drug: Glucomannan (GNN)
DrugBank: Konjac mannan (DB14963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucomannan (GNN) at a dosage of 2.52 g/d (1 sachet of 1.26 g 2 times a day) for 4 weeks
Trial: 23716985
Drug: Placebo (maltodextrin)
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin) at the same dosage for 4 weeks
Trial: 21846985
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily gentamicin dosing